Nephron-Sparing Surgery for the Treatment of Renal Cell Carcinoma 4 to 7 cm in Size by Pertia, Ambrosi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Nephron-Sparing Surgery for the Treatment of
Renal Cell Carcinoma 4 to 7 cm in Size
Ambrosi Pertia, Laurent Managadze and
Archil Chkhotua
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53830
1. Introduction
The incidence of kidney cancer is gradually increasing over the past 2–3 decades [1]. 60 920
new cases of RCC have been diagnosed in the US in 2011 and 13 120 died of cancer [2]. The
widespread use of modern radiological studies has substantially changed clinical presenta‐
tion of the renal tumors. Currently, there is a trend towards more frequent diagnosis of
asymptomatic, incidental, smaller lesions [1, 3]. Nephron sparing surgery (NSS) was initially
used in the treatment of renal cell carcinoma (RCC) only for absolute and relative indica‐
tions [4]. Excellent oncological outcome and reduced morbidity after NSS have led to more
frequent use of organ preserving surgery in many centers [4-7]. Elective NSS is currently the
treatment of choice for T1a tumors (<4 cm) in the patients with a normal contralateral kid‐
ney. Its safety and oncological results have been evaluated in numerous studies [3, 8-10].
The role of NSS in the tumors of 4–7 cm in size is less evaluated and controversial. It could
be technically challenging as well [10]. The existing studies suggest that this policy might be
feasible and safe. In this paper we present our single centre experience in using the NSS for
RCC of 4–7 cm in size.
2. Technique of nephron-sparing surgery
All patients were operated through extraperitoneal, extrapleural incision above the 12th rib
in 38 cases and above the 11th rib in 19 cases. The kidney was completely mobilized to ex‐
clude the presence of satellite tumors. Peritumoral fat was left in situ. Sharp incision of the
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renal capsule was performed 2 to 3 mm away from the tumor margin. The renal pedicle was
isolated completely and the renal artery was clamped just before beginning the incision on
the renal capsule. The venous clamping was not used in any case. For diminishing the out‐
comes of renal ischemia vigorous hydration, infusion of Mannitol before the arterial clamp‐
ing, and renal hypothermia was adopted in all cases. Tumors were enucleated without a
layer of normal parenchyma in 17 cases and enucleoresection was performed in 40 cases.
Tumor bed was inspected very carefully on the presense of residual tissue. Intraoperative
frozen section of tumor bed was routinely performed. The results of frozen section were
negative in all cases. The data of the patients who underwent nephrectomy due to positive
margins on the frozen section were not included in the study. The visible bleeding vessels
and opened calices were closed using running sutures. Finally, tumor bed was coagulated
carefully for haemostatic and partly for oncological reasons. The coagulation was performed
by means of diathermy. The parenchymal defect was closed using absorbable interrupted
sutures. In case of large capsular defect it was covered with free peritoneal graft.
The stained slides from all tumor specimens were reviewed by urological pathologist. Short‐
ly, the resected kidneys were evaluated macroscopically. The maximal tumor size was meas‐
ured and 1.5 x 2cm tissue samples were taken for further assessment. Specimens were fixed,
stained and evaluated by the same pathologist according to conventional technique. Patho‐
logical tumor staging was performed according to the 2002 TNM staging system [11] and
nuclear grade was assigned according to the Furhman’s grading system [12]. The removed
tumor specimen was always inspected by pathologists and the surgical margins were inked.
Patients were followed with renal functional tests, chest X-ray, abdominal ultrasound or CT
every 3 months during the first year, once in 6 months for the next two years and annually
thereafter. In terms of statistical analysis the probability of cumulative and cancer-specific
survival was estimated by the Kaplan-Meier method using the whole number of events.
3. Results
We retrospectively reviewed the records of 57 patients who underwent NSS at our institu‐
tion from 1994 to 2011. The table 1 describes the clinical and pathological features of 57 pa‐
tients operated at our institution. All patients were carefully evaluated to exclude the
presence of distant metastases. Preoperative evaluation included: ultrasonography of the
kidney, CT of the abdomen and chest X-ray in all patients. Renal function was assessed by
measuring serum creatinine level and creatinine clearance.
The mean follow-up was 70.1 months (range: 10-157 months). Out of the 57 patients 35
(61.4%) were male and 22 (38.6%) were female. The median patient age was 53.1 years
(range: 37-68 years). Left side tumor was detected in 34 (59.6%) cases and right side in 23
(40.4 %) cases. The tumor was located in the upper pole in 21 (36.8 %), in the mid kidney in 7
(12.2 %) and in the lower pole in 29 (51%) patients. Tumors were located peripherally in 46
(80.7%) cases and the central tumor location was detected in 11 (19.3%) cases. The peripheral
location was defined as: peripherally located and enveloped by cortical parenchyma tumor,
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without extension into the renal sinus. At the diagnosis 53 (92.9 %) tumors were detected
incidentally and 4 (7.1%) were associated with microscopic haematuria. The NSS was per‐
formed for absolute indications in 5 (8.7%) and for relative indications in 11 (19.9%) cases. 41
(71.9%) patients underwent NSS for elective indications.
Age at surgery (years) 53.1 (37-68)
Gender
Male 35 (61.4 %)
Female 22 (38.6 %)
Tumor location
Left 34 (59.6%)
Right 23 (40.4 %)
Upper pole 21 (36.8 %)
Mid kidney 7 (12.2 %)
Lower pole 29 (51%)
Central 11 (19.3%)
Peripheral 46 (80.7%)
Clinical presentation
Incidental 53 (93%)
Presented by haematuria, pain etc. 4 (7%)
Tumor size (mm.) 48.1 (41-70)
Stage
pT1b 53 (93%)
pT3a 4 (7%)
Fuhrman grade
G1 22 (38.6 %)
G2 27 (47.4 %)
G3 8 (14 %)
Histological subtype (%)
Clear cell 49 (85.9 %)
Pappilary 5 (8.7 %)
Chromophobe 2 (3.7 %)
Cystic RCC 1 (1.75 %)
Surgical complications
Bleeding 1(1.75 %)
Urinary leakage 4 (7%)
Disease Recurrence
Local recurrence 2 (3.5 %)
Distant metastases 4 (7%)
Table 1. Clinico-pathological characteristics of 57 patients operated with NSS.
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The mean tumour size was 48.1 mm. (range: 41-70 mm.). The mean tumor size in the patients
who underwent NSS for elective indications was 44.7 mm. and in the patients who underwent
NSS for absolute and relative indications was 65.8 mm (p<0.04). The difference between the lat‐
er two groups was not significant. Fifty three out of 57 tumors were pT1b (92.9 %) and 4 (7.1%)
were pT3a. Pathological T3a stage was confirmed by tumor microinvasion into the perirenal
fat. The final pathological evaluation did not reveal any case of tumor extension out of the
inked area of the surgical specimens. Grade I tumor was diagnosed in 22 (38.6%), Grade 2 in 27
(47,4%) and Grade 3 in 8 (14%) cases. Morphological evaluation revealed 49 (85.9%) clear cell, 5
papillary (8.7%), 2 chromophobe (3.7%) and 1 cystic (1.75%) RCCs.
The mean duration of renal ischemia was 22 minutes (range: 18-35 mm.). No perioperative
mortality and/or serious general complications (myocardial infarction, deep venous throm‐
bosis etc.) have been observed. Postoperative complications occurred in 5 (8.8%) patients in‐
cluding: one (1.7%) postoperative bleeding and 4 (7%) urinary fistulas. The bleeding was
observed in peripherally located, large (6 cm. in size) tumor operated for absolute indica‐
tion. Urinary leakage occurred in two patients operated for centrally located (18.1%) and in
two (4.2%) peripherially located tumors. This difference was statistically significant in favor
of peripherially located tumors (p<0.0001). All patients required a double “J” stenting. Peri‐
renal hematoma was observed in 2 (3.5%) cases but did not need any intervention and re‐
solved spontaneously. Renal functions were stable in all patients during the follow-up
period with a median postoperative creatinine level of 0.9 mg/dl (range: 0.7–1.4 mg/dl). The
median hospital stay was 6 days (range: 4-15 days).
The tumor has recurred in 6 (10.5%) patients. Of them, local recurrence was detected in 2
(3.5%) and systemic recurrence in 4 (7%) patients. At the end of the follow-up overall surviv‐
al was 85.8%, the disease-free survivals was 88.2 %. Both disease-free and overall survival
were significantly better in groups of relative and elective indications as compared with ab‐
solute indication (p=0.014 and p=0.023, respectively) (Figure 1).
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Figure 1. Cancer-specific survival in the patients with elective, relative and absolute indications for NSS.
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4. Discussion
The widespread use of modern radiological modalities substantially changed clinical pre‐
sentation of renal tumors in recent decades. Currently, there is a trend towards the diagnosis
of asymptomatic, incidental, smaller lesions at lower stages [1, 3, 10]. The local disease re‐
currence is the major drawback of NSS mostly due to the incomplete resection of the pri‐
mary tumor. In this due radical nephrectomy still remains the gold standard for the
treatment of RCC [4, 10].
Improved diagnostic and surgical techniques have led to wider use of NSS. Uzzo RG. and
Novick AC. in their review of the results of more than 1800 cases of NSS have showed that
the true biological significance of multicentric renal tumors and its implications for NSS re‐
mains to be elucidated [3]. In a prospective, randomized EORTC (European Organisation for
Research and Treatment of Cancer) phase 3 study comparing open partial nephrectomy
(OPN) with open radical nephrectomy (ORN) in small renal tumors (< 5 cm.) found compa‐
rable oncological results in the both arms [8, 9]. Moreover, excellent 5 and 10 year disease-
free survival rates of 98.5% and 96.7% have been reported after NSS in non-randomized
studies [5-7]. These data are now widely accepted. Finally, the recent evidence favoring the
NSS over radical nephrectomy in the prevention of chronic kidney disease and possibly
linking it to a better overall survival will constitute a strong argument for wider use of NSS.
On the other hand, NSS is technically more demanding than RN even for small renal tumors
[13]. The previous report of the EORTC 30904 trial revealed that complication rate in NSS
was slightly higher than in radical nephrectomy [8].
Based on the success of NSS in the tumors of ≤ 4 cm, it has been increasingly used for the
treatment of 4-7 cm. tumors in case of a normal contralateral kidney. Leibovich BC. Et al.
retrospectively compared the results of NSS and radical nephrectomy in the tumors of 4 to 7
cm in size. There were no statistically significant differences in cancer-specific survival and
distant metastases-free survival after adjusting for important pathological features. Thus,
the authors concluded that the NSS has excellent results for the treatment of 4 to 7 cm renal
tumors in appropriately selected patients [14].
Dash A. et al. compared the outcomes of the patients who had an elective partial or radi‐
cal  nephrectomy for  clear  cell  renal  cell  carcinoma of  4–7 cm.  in size.  With the median
follow-up of 21 months the authors failed to show that radical nephrectomy was associ‐
ated with a better cancer control than the NSS. In terms of functional results the authors
found that  the serum creatinine level  3  months after  surgery was significantly lower in
the patients who had NSS [15].
Becker F. et al. reported the excellent results of NSS performed for elective indications. 69
patients with the tumor size of more than 4 cm. underwent NSS. After a mean follow-up of
6.2 years seven patients (10.1%) have died, none of them due to the tumor-related causes.
Tumor recurrence was detected in four patients (5.8%). The 5-year overall survival was
94.9%. The 10-year and 15-year overall survival was 86.7%. Cancer-specific survival was
100% at 5, 10, and 15 years. The authors concluded that the selected patients with localized
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RCC of > 4 cm. can be treated with elective NSS providing optimal long-term outcome. The
surgeon’s decision for organ-preserving surgery should depend on the tumor location and
technical feasibility rather than on the tumor size [16].
Pahernick S. et al. compared the results of NSS for the tumors of less and more than 4 cm. in
size. Out of 474 treated patients 102 had the tumor of more than 4 cm. The mean follow-up
was 4.7 years. The 5 and 10-year cancer-specific survival for small and large tumors were:
97.9% and 95.8%, 94.9% and 95.8%, respectively. In contrast to the tumor size, stage pT3a
was associated with a significantly higher risk of tumor related death. The authors advocat‐
ed that the surgeon’s decision with regard to the organ preservation should consider the tu‐
mor location and safe surgical resectability, rather than the tumor size [17]. This conclusion
has been later supported by Antonelli A. et al. [18].
Joniau S. et al. presented their results of NSS for the patients with bigger than 4 cm renal
tumors. The following data have been collected and analyzed: surgical indication, tumor
characteristics, complications, serum creatinine level, time to recurrence and time to the pa‐
tient death. Local cancer control has been achieved in the vast majority of patients. The renal
function was preserved in the patients with elective indications. NSS for absolute indica‐
tions was significantly correlated with the loss of renal function but not with a cancer-specif‐
ic survival [19].
In our study the local disease recurrence was detected in 2 (3.5%) and the systemic recur‐
rence in 4 (7%) patients. We could not reveal any changes in the serum creatinine level pre-
and postoperatively in the both groups, despite cold ischemia which was used in all
patients. Both, the cancer-specific and overall survival was significantly better in the groups
of relative and elective indications as compared with the absolute indication (p<0.014 and
p<0.023, respectively). These data are similar to the results of the eight-institution multicen‐
tre review of 1048 NSS procedures [13].
It has been shown by Badalato GM. et al. in their recent publication that the oncological effi‐
cacy of NSS for pT1b renal tumors was comparable to that of radical nephrectomy [20]. The
authors compared the NSS with radical nephrectomy in the patients with T1b RCC using a
propensity scoring approach. 11 256 cases of 4-7 cm. tumors that underwent partial or radi‐
cal nephrectomy have been evaluated. The propensity score analysis was used to adjust for
the potential differences in the baseline characteristics of the patients between the two
groups. Overall and disease-free survival of the patients was compared in stratified and ad‐
justed analysis, controlling for propensity scores. For the entire patient cohort, no difference
in the survivals was found in the NSS and radical nephrectomy groups. The survival differ‐
ence between the groups in a propensity-adjusted cohort of patients could not be confirmed
even when stratified by the tumor size and patient age.
We’ve observed that the NSS for centrally located tumors was associated with a higher com‐
plication rate. This goes in accordance with the data of Ficarra V. et al. who recently pro‐
posed a new tumor scoring system [21]. According to the authors this system can better
predict the complications after NSS than linear tumor size.
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The weak points of our study are retrospective nature and absence of control group consist‐
ing of RN patients. However, the prospective randomized study is very difficult to conduct
especially in the era of minimally invasive approaches for the treatment of RCC.
5. Conclusion
In conclusion, the NSS is a feasible procedure for RCCs of 4-7 cm in size. The local cancer
control can be achieved in most patients. Oncological outcome of the treatment is negatively
related with the tumor size. Long-term prospective studies on the higher number of patients
are required to prove the similar oncological efficacy of NSS and radical nephrectomy in the
RCCs of 4-7 cm. in size.
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